Multinational partners and licensors
“Partnership of choice programmes are integral to the Adcock Ingram business model”
| How do we create value for our multinational partners and licensors |  |
By ensuring partner satisfaction with the service and results delivered through the specific arrangements. |
| How do our operations affect our multinational partners and licensors |  |
Achievement of commercial and partnership goals; alignment with international best practice standards for product promotion and regulatory adherence. |
| How do we engage with our multinational partners and licensors | |
Regular reviews with partners both domestically and internationally to ensure the Group retains a high profile with existing and prospective partners. |
| What are the associated risks and opportunities for us and our multinational partners and licensors | |
Constant management of the diverse expectations of Partners is an ongoing focus for the business. The divisionalisation has assisted in the monitoring and management of these relationships, but the high level of global consolidation, and management and portfolio changes within multinationals, means that these arrangements can be placed at risk |
| What are associated strategic objectives for ensuring that the multinational partners and licensors’ needs are met | |
Extending our MNC relationships into distribution activities. In the Prescription Division, pursuing generic partnership relationships to improve our product offering and obtaining clone molecules and co-promotion opportunities from our innovator MNC partners. In the Hospital Division, investigating agency or licence agreements with companies whom we do not currently partner, in categories where we are not active. |